CA2423436A1 - Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations - Google Patents

Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations Download PDF

Info

Publication number
CA2423436A1
CA2423436A1 CA002423436A CA2423436A CA2423436A1 CA 2423436 A1 CA2423436 A1 CA 2423436A1 CA 002423436 A CA002423436 A CA 002423436A CA 2423436 A CA2423436 A CA 2423436A CA 2423436 A1 CA2423436 A1 CA 2423436A1
Authority
CA
Canada
Prior art keywords
ncam
cell
fragment
cell activation
functional derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002423436A
Other languages
English (en)
Inventor
Anthony Montgomery
Larissa Balaian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2423436A1 publication Critical patent/CA2423436A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

L'invention concerne de façon générale le domaine de l'immunologie ou de la neuroimmunologie. Elle concerne, en particulier, un procédé servant à diminuer ou à inhiber l'activation des lymphocytes T et consistant à administrer une quantité efficace d'un antagoniste de NCAM L1 à un mammifère nécessitant la diminution ou l'inhibition de l'activation des lymphocytes T, ce qui permet de diminuer ou d'inhiber l'activation des lymphocytes T chez ledit mammifère. Elle concerne, de plus, des combinaisons et des procédés combinés servant à moduler l'activation des lymphocytes T. Elle concerne également un procédé servant à potentialiser l'activation des lymphocytes T et consistant à administrer une quantité efficace d'une molécule d'adhérence aux cellules neurales multimérisée L1 (NCAM L1) ou un de ses dérivés ou fragments fonctionnels, ou un acide nucléique codant L1 ou ledit dérivé fonctionnel ou ledit fragment, ou un agent amplifiant la production et/ou la fonction de stimulation combinée dudit L1 à un mammifère nécessitant l'activation des lymphocytes T, ce qui permet de potentialiser l'activation des lymphocytes T chez ledit mammifère.
CA002423436A 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations Abandoned CA2423436A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23755500P 2000-10-02 2000-10-02
US60/237,555 2000-10-02
PCT/US2001/030864 WO2002028440A1 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2423436A1 true CA2423436A1 (fr) 2002-04-11

Family

ID=22894231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002423436A Abandoned CA2423436A1 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1328298A4 (fr)
JP (1) JP2004531457A (fr)
AU (1) AU2002213001A1 (fr)
CA (1) CA2423436A1 (fr)
WO (1) WO2002028440A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
CA3007233A1 (fr) 2015-12-02 2017-06-08 Agenus Inc. Anticorps et leurs methodes d'utilisation
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation

Also Published As

Publication number Publication date
JP2004531457A (ja) 2004-10-14
AU2002213001A1 (en) 2002-04-15
WO2002028440B1 (fr) 2002-05-30
EP1328298A1 (fr) 2003-07-23
WO2002028440A1 (fr) 2002-04-11
EP1328298A4 (fr) 2005-05-04

Similar Documents

Publication Publication Date Title
AU2017261541B2 (en) Inhibitors of T-cell activation
Freeman et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
Linsley et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Harris et al. The role of B7 costimulation in T‐cell immunity
EP1234031B2 (fr) Nouvelle molécule immunorégulatrice b7-h1,
Bluestone Is CTLA-4 a master switch for peripheral T cell tolerance?
KR100609441B1 (ko) 면역성 질환 치료제
AU2009288730B2 (en) Compositions of PD-1 antagonists and methods of use
Wallace et al. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment.
ZA200208897B (en) Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking LFA-1 mediated adhesion.
JPH09510211A (ja) Ｔ細胞の不応答性を調節する方法
Scheipers et al. Role of the CTLA-4 receptor in T cell activation and immunity: physiologic function of the CTLA-4 receptor
Rietz et al. New B7 family members with positive and negative costimulatory function
Balaian et al. The human neural cell adhesion molecule L1 functions as a costimulatory molecule in T cell activation
CA2423436A1 (fr) Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations
US20030040477A1 (en) Methods and compositions for modulating t cell activation and uses thereof
WO2001079300A9 (fr) Antigene a liaison de surface reliant des portions d'anticorps se liant au ctla-4 et au cd28 et applications
EP0795014A1 (fr) Genes purifies codant des antigenes de surface de cellules mammaliennes; proteines et anticorps
Kumaresan et al. Molecular characterization of the rat NK cell receptor 2B4
Yang et al. The role of B7-2 (CD86) in tumour immunity
Zheng et al. Co-stimulatory molecules B7-1 and B7-2 as experimental therapeutic targets
Alenzi et al. Role of CTLA-4 in xenotranplantation
Buhlmann et al. 1. WHAT IS COSTIMULATION?
Goldberg et al. Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production By Gordon J. Freeman,* Frank Borrielloj Richard J. Hodes's Hans Reiser, ll John G. Gribben'Judy W. Ng,* Jinny Kim, $
Alegre et al. CTLA-4: Its Role in the Immune Response

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead